Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on April 16, 2025
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board
GlobeNewswire
·
April 16, 2025
CAMBRIDGE, Mass. and HOUSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics, announces that Massachusetts …
electroCore to Participate at the Planet MicroCap Showcase
GlobeNewswire
·
April 16, 2025
ROCKAWAY, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Planet MicroCap Showcase taking place at the Paris …
Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
April 16, 2025
Advancing development of next-generation precision Antibody Drug Conjugates (ADCs) to address multiple indications across a range of cancer types Continued progress of lead program, AKTX-101, for the treatment of solid tumors Platform technology to fuel …
Best Appetite Suppressants - Natural Over the Counter (OTC) Appetite Suppressant for Hunger Control & Fat Burner ( Men & Women) - By Phenq CrazyBulk in USA
GlobeNewswire
·
April 16, 2025
Albany, New York, April 16, 2025 (GLOBE NEWSWIRE) -- Struggling to control your appetite and cravings? You're not alone. Maintaining a healthy weight can be a constant battle in the modern world of tempting high-calorie foods and sedentary lifestyles. But …
BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer
GlobeNewswire
·
April 16, 2025
Median overall survival of 17.3 months in Bria-IMT™ treated patients with hormone receptor positive (HR+) metastatic breast cancer markedly exceeds historical data of 14.4 months in TRODELVY® (sacituzumab govitecan-hziy) in similar heavily pre-treated …
LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation
GlobeNewswire
·
April 16, 2025
Exemption from the $5.1 million repayment obligation strengthens LAVA’s balance sheet Underscores focus on cost curtailment and strategic option evaluation UTRECHT, The Netherlands and PHILADELPHIA, April 16, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V …
Oxford Scientists Reveal Sunlight-Powered Anti-Cancer Breakthrough
GlobeNewswire
·
April 16, 2025
OXFORD, United Kingdom, April 16, 2025 (GLOBE NEWSWIRE) -- Dr. Daniel Chen, at the University of Oxford and Chief Scientist at biotech startup Oxperial BioHealth, revealed their major breakthrough in cancer prevention—a sunlight-powered technology that …
Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis
GlobeNewswire
·
April 16, 2025
Company-sponsored clinical trial will be initiated at FAU Erlangen-Nuremberg in Germany and Università Cattolica del Sacro Cuore, Rome in Q2 2025 CLN-978 is also being studied in the U.S., Europe, and Australia for systemic lupus erythematosus CAMBRIDGE, …
Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer
GlobeNewswire
·
April 16, 2025
CONSHOHOCKEN, Pa., April 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that …
Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025
GlobeNewswire
·
April 16, 2025
CHATHAM, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that …
Tilray Brands Ranks #4 on the Brewers Association List of Top Producing Craft Brewers in the United States
GlobeNewswire
·
April 16, 2025
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Tilray Beverages, a division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), is pleased to announce that its U.S. Beverage division has achieved a significant milestone, ranking #4 on the Brewers …
INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology
GlobeNewswire
·
April 16, 2025
Boca Raton, Florida, US, April 16, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announced a major intellectual property …
Spectral Medical Completes Tigris Trial Enrollment
GlobeNewswire
·
April 16, 2025
157 patients enrolled Topline results expected to be released in August 2025 Company to host Corporate Update Call on May 15, 2025 TORONTO, April 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage …
DIAGNOS announces major advances in Cybersecurity certification by the Cyber Defense Operations Center (COCD) for its CARA System application
GlobeNewswire
·
April 16, 2025
BROSSARD, Quebec, April 16, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of certain ophthalmic health issues using advanced technology based on Artificial …
DIAGNOS annonce des avancées majeures dans sa certification de Cybersécurité par le Centre opérationnel de cyberdéfense (COCD) pour son application CARA System
GlobeNewswire
·
April 16, 2025
BROSSARD, Québec, 16 avr. 2025 (GLOBE NEWSWIRE) -- Diagnos inc. (« DIAGNOS » ou la « Société ») (Bourse de croissance TSX : ADK, OTCQB : DGNOF, FWB : 4D4A), un pionnier de la détection précoce de certains problèmes de santé ophtalmique à l'aide d'une …
RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME
GlobeNewswire
·
April 16, 2025
RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME ISTURISA® is a cortisol synthesis inhibitor that blocks the enzyme 11β-hydroxylase to help normalize …
Prime Biome (Updated 2025): A Comprehensive Review of the Groundbreaking Skin-Gut Axis Supplement
GlobeNewswire
·
April 16, 2025
ST. PETERSBURG, Fla., April 16, 2025 (GLOBE NEWSWIRE) -- Prime Biome is a revolutionary gut-skin health supplement that has taken center stage in holistic wellness. This probiotic formula promises simultaneous benefits for skin radiance and digestive …
Conditional Issuance of Shares
GlobeNewswire
·
April 16, 2025
INSIDE INFORMATION REGULATED INFORMATION Conditional Issuance of Shares Mont-Saint-Guibert, Belgium – April 16, 2025, 8:00 am CET / 2:00 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), today announced a conditional issuance …
Basilea berichtet über Präsentation neuer Daten zu Fosmanogepix, Isavuconazol (Cresemba®) und Ceftobiprol (Zevtera®) auf dem Fachkongress ESCMID Global 2025
GlobeNewswire
·
April 16, 2025
Allschwil, 16. April 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, gab …
Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025
GlobeNewswire
·
April 16, 2025
Allschwil, Switzerland, April 16, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today scientific …